Pfizer’s blockbuster safety issue jumps the Atlantic as EMA launches its own review of Xeljanz

Pfizer’s Xeljanz woes have spread to Europe.

After the FDA announced earlier this week that it is investigating the increased risk of blood clots and death linked to their blockbuster JAK inhibitor seen in a post-marketing study, the EMA says they’ll now make their own assessment on the safety of the drug.